R406 reduces lipopolysaccharide-induced neutrophil activation.

Autor: Warner S; Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA., Teague HL; Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA., Ramos-Benitez MJ; Basic Science Department, Microbiology Division, School of Medicine, Ponce Health Sciences University, Ponce, PR, USA., Panicker S; Laboratory of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Allen K; Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA., Gairhe S; Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA., Moyer T; Flow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Parachalil Gopalan B; Laboratory of Sickle Thrombosis and Vascular Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Douagi I; Flow Cytometry Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA; NIH Center for Human Immunology, Inflammation, and Autoimmunity, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Shet A; Laboratory of Sickle Thrombosis and Vascular Biology, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Kanthi Y; Laboratory of Vascular Thrombosis and Inflammation, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Suffredini AF; Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA., Chertow DS; Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA; Laboratory of Virology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Strich JR; Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Critical Care Medicine Department, National Institutes of Health Clinical Center, National Institutes of Health, Bethesda, MD, USA. Electronic address: jeffrey.strich@nih.gov.

Publikováno v: Cellular immunology [Cell Immunol] 2024 Sep-Oct; Vol. 403-404, pp. 104860. Date of Electronic Publication: 2024 Jul 26.

Isoquercetin for thromboinflammation in sickle cell disease: a randomized double-blind placebo-controlled trial.

Autor: Lizarralde-Iragorri MA; Sickle Thrombosis and Vascular Biology Lab, Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Parachalil Gopalan B; Sickle Thrombosis and Vascular Biology Lab, Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Merriweather B; Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Brooks J; Office of the Clinical Director, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Hill M; Office of the Clinical Director, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Lovins D; Office of the Clinical Director, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Pierre-Charles R; Office of the Clinical Director, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Cullinane A; Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD., Dulau-Florea A; Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD., Lee DY; Biochemistry Core Facility, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Villasmil R; Flow Cytometry Core Facility, National Eye Institute, National Institutes of Health, Bethesda, MD., Jeffries N; Office of Biostatistics Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD., Shet AS; Sickle Thrombosis and Vascular Biology Lab, Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD.

Publikováno v: Blood advances [Blood Adv] 2024 Jan 09; Vol. 8 (1), pp. 172-182.